基本情報
- 標準SMILES
CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1- InChIKey
SFBODOKJTYAUCM-UHFFFAOYSA-N- 分子式
- C18H16O3
- 平均分子量
- 280.3 g/mol
- 単同位体質量
- 280.10994437
名称と識別子
- 優先名称
- Ipriflavone
- IUPAC
- 3-phenyl-7-propan-2-yloxychromen-4-one
- 現地名
- イプリフラボン
- 英語名
- Ipriflavone
- 分子式
- C18H16O3
- 分子量
- 280.32
名称と別名
名称をさらに表示
データベース識別子
- CAS
35212-22-7- PubChem CID
- 3747
- DTXSID
DTXSID5040679- ChEMBL
CHEMBL165790- ChEBI
CHEBI:31719- UNII
- 80BJ7WN25Z
- EC Number
- 609-092-2
- Nikkaji
- J19.468I
物性
構造計算による物性
- XLogP
- 4
- 極性表面積
- 35.5 Ų
- 水素結合供与体数
- 0
- 水素結合受容体数
- 3
- 回転可能結合数
- 3
- 重原子数
- 21
- 形式電荷
- 0
- 複雑度
- 407
実験および物理化学的性質
Collision Cross Section
161.54 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];175.72 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards];155.27 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
164.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 116 · 116-120 °C(lit.)
- 沸点
- 363.04 °C · 363.04°C (rough estimate)
- 比重(密度)
- 1.217 · 1.2170 (rough estimate)
- 屈折率
- 1.47 · 1.4700 (estimate)
- 貯蔵温度
- Sealed in dry,Room Temperature
- 溶解性
- 20 · DMF:20.0(Max Conc. mg/mL);71.35(Max Conc. mM)DMF:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.71(Max Conc. mM)DMSO:33.11(Max Conc. mg/mL);118.11(Max Conc. mM)Ethanol:1.5(Max Conc. mg/mL);5.35(Max Conc. mM)
- 外見
- powder to crystal
- 色
- White to Almost white
- Merck
- 14 · 14,5074
- InChI
- InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
- InChIKey
- SFBODOKJTYAUCM-UHFFFAOYSA-N
- SMILES
- C1OC2=CC(OC(C)C)=CC=C2C(=O)C=1C1=CC=CC=C1
- LogP
- 4.245 · 4.245 (est)
- CAS データベース
- 35212 · 35212-22-7(CAS DataBase Reference)
化学的性質
化学的特性white powder
安全と法規制
安全データ
- wgk
- 2
- rtecs
- DJ3100500
- hs_code
- 29329990
- risk_code
- 36/37/38
- hazard_code
- Xi
- safety_code
- 24/25-36/37/39-27-26
- ストレージクラス
- 11 - Combustible Solids
化学と産業
薬理情報
ATC Code
M - Musculo-skeletal system;M05 - Drugs for treatment of bone diseases;M05B - Drugs affecting bone structure and mineralization;M05BX - Other drugs affecting bone structure and mineralization;M05BX01 - Ipriflavone
QM - Musculo-skeletal system;QM05 - Drugs for treatment of bone diseases;QM05B - Drugs affecting bone structure and mineralization;QM05BX - Other drugs affecting bone structure and mineralization;QM05BX01 - Ipriflavone
応用分野
用途骨粗鬆症における骨量減少の改善研究用。
用途直接的な骨吸収抑制作用、エ ストロゲンのカルシトニン分泌促進作用を示 します。
用途直接的な骨吸収抑制作用、エ ストロゲンのカルシトニン分泌促進作用を示 します。
説明Ipriflavone, a derivative of isoflavone, is a calcium metabolism regulator useful in the treatment of primary and secondary osteoporosis, as well as disorders of osteogenesis. It appears to be without significant side-effects.
使用7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone) has been used as a model drug in a study to functionalize the mesoporous bioactive glasses (MBG). Study suggested that since ipriflavone is a hydrophobic anti-osteoporotic drug, it easily attaches to the surface of MBG and results in long-term drug delivery.
一般的な説明7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one (Ipriflavone), a synthetic flavonoid, is reported to stimulate the activity of osteoblasts. It is reported to promote the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like (ROB) cells as well as the activity of alkaline phosphatase. Ipriflavone, an isoflavone derivative, is a new drug used to decrease bone loss in osteoporosis.
上流・下流製品情報
上流原料
サプライヤー50 社
補足説明
定義ChEBI: Ipriflavone is a member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. It has a role as a bone density conservation agent. It is a member of isoflavones and an aromatic ether.
関連反応
関連ノート
読み込み中…